Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021
June 02, 2021 at 02:43 pm EDT
Share
Rasna Therapeutics, Inc. announced earnings results for the second quarter ended March 31, 2021. For the second quarter, the company announced operating loss was USD 93,623 compared to USD 181,580 a year ago. Net loss was USD 266,361 compared to USD 190,973 a year ago. For the half year, operating loss was USD 248,563 compared to USD 330,861 a year ago. Net loss was USD 438,222 compared to USD 349,015 a year ago. Basic eps - continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.01 a year ago.
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
ACTAVIA LIFE SCIENCES, INC. 
